Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i> -mutant ganglioglioma
Mehdi Touat(Broad Institute), Anna Luisa Di Stefano(Hôpital Foch), Keith L. Ligon(Brigham and Women's Hospital), S. Auliac(Centre National de la Recherche Scientifique), Sorin Aldéa, Julien Savatovsky(Fondation Ophtalmologique Adolphe de Rothschild), Chiara Villa(Centre National de la Recherche Scientifique), Géraldine Perkins(Assistance Publique – Hôpitaux de Paris), Hélène Blons(Délégation Paris 5), Marc Sanson(Centre National de la Recherche Scientifique), Antoine Hollebecque(Institut Gustave Roussy), Karine Sejean(Hôpital Foch), Pierre Laurent‐Puig(Inserm), Julie Gratieux(Centre National de la Recherche Scientifique), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Anne‐Paule Gimenez‐Roqueplo(Délégation Paris 5)
Cited by 25
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k